# Regulation of tumor-associated phagocyte physiology during tumor cell clearance > **NIH NIH R00** · SLOAN-KETTERING INST CAN RESEARCH · 2020 · $248,999 ## Abstract Project Summary/Abstract Our current knowledge of how a phagocyte manages engulfment and digestion of apoptotic corpses remains sparse. Understanding the mechanisms by which a phagocyte engulfs and digests corpses is particularly important, because immune evasion by cancer relies on phagocytosis of cancer cells to establish a tolerogenic microenvironment. We identified a network of solute carrier (SLC) proteins in phagocytes engulfing apoptotic Jurkat lymphoma cells associated with distinct physiological processes and demonstrated functional relevance for two SLCs: SLC2A1 (facilitates corpse uptake via glucose transport) and SLC16A1 (required for export of the anti-inflammatory molecule lactate). In this application, we show that phagocytes regulate several distinct functional programs in response to corpse engulfment and digestion. One of these programs includes SLC12A2 which, together with the upstream kinases WNK1/OSR1/SPAK, act as a physiological ‘brake’ on apoptotic Jurkat cell engulfment via chloride sensing/flux and cell volume regulation. This application proposes to test the hypothesis that deletion/ inhibition of the SLC12 pathway will lead to increased lung adenocarcinoma clearance in vitro/ in vivo and induce a clinically beneficial switch from ‘tolerogenic’ to ‘immunogenic’ cancer cell clearance. Preliminarily, SLC12A2-deficient phagocytes actively engulfing apoptotic Jurkat cells exhibited suppression of the canonical anti-inflammatory transcriptional signature and induction of a pro-inflammatory signature highlighted by a robust type I interferon response. Furthermore, using bioactive small molecules targeting SLC12A2 or WNK1, we provide proof-of-principle that targeting this pathway leads to boosted Jurkat cell clearance in vivo. These studies will provide further insight into a previously unknown cell clearance regulatory pathway, the role of this pathway in lung adenocarcinoma development/ progression, and explore the hypothesis that genetic/ pharmaceutical perturbation of the SLC12 pathway will promote increased cancer cell clearance and a stronger anti-cancer immune response. During the mentored phase of this application, I will master experimental techniques for the lungs such as intratracheal injection and bronchioalveolar lavage fluid collection as well as establish crucial lung adenocarcinoma models proposed herein. I will establish new conditional deletion mice to evaluate genetic perturbation of the SLC12 pathway on the development/ progression of lung adenocarcinoma. Together with colleagues, we will develop new tools to assess the importance of volume regulation during tumor cell clearance in vivo, allowing us to understand how phagocytes establish immune tolerance during lung adenocarcinoma development/ progression. With the guidance of my mentoring committee, I will strengthen my scientific and professional skillsets in preparation for the independent phase. During the independent phase, I will explore targeting the ... ## Key facts - **NIH application ID:** 9999544 - **Project number:** 5R00CA237728-03 - **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH - **Principal Investigator:** Justin S Perry - **Activity code:** R00 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2020 - **Award amount:** $248,999 - **Award type:** 5 - **Project period:** 2019-07-01 → 2022-06-30 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/9999544 ## Citation > US National Institutes of Health, RePORTER application 9999544, Regulation of tumor-associated phagocyte physiology during tumor cell clearance (5R00CA237728-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9999544. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*